TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma

被引：5

作者：

Mehta, Anurag ^{[1
]}

Diwan, Himanshi ^{[1
]}

Bansal, Divya ^{[1
]}

Gupta, Manoj ^{[2
]}

机构：

[1] Rajiv Gandhi Canc Inst & Res Ctr RGCIRC, Dept Lab Mol & Transfus Serv, New Delhi 110085, India

[2] Rajiv Gandhi Canc Inst & Res Ctr RGCIRC, Dept Nucl Med, New Delhi, India

来源：

JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE | 2022年 / 56卷 / 01期

关键词：

BRG1; Lung; Non-small cell lung carcinoma; SMARCA4; Thyroid transcription factor 1;

D O I：

10.4132/jptm.2021.09.16

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non-small cell lung carcinomas. We present here a case of SD-LUAD with curious thyroid transcription factor 1 (TTF1) expression in a morphologically heterogenous lung adenocarcinoma. The better differentiated area showed preservation of TTF1 expression, and a poorly differentiated tumor had loss of TTF1 expression with universal BRG1 loss.

引用

页码：53 / 56

页数：4

共 50 条

[1] Loss of BRG1/SMARCA4 Expression in Pancreatic Ductal Adenocarcinoma
Lin, M.
Scrimieri, F.
Nguyen, T.
Wolfgang, C. L.
Iacobuzio-Donahue, C.
Maitra, A.
Goggins, M.
Eshleman, J.
Olino, K.
Kern, S. E.
Hruban, R. H.
MODERN PATHOLOGY, 2010, 23 : 363A - 363A
[2] Loss of BRG1/SMARCA4 Expression in Pancreatic Ductal Adenocarcinoma
Lin, M.
Scrimieri, F.
Nguyen, T.
Wolfgang, C. L.
Iacobuzio-Donahue, C.
Maitra, A.
Goggins, M.
Eshleman, J.
Olino, K.
Kern, S. E.
Hruban, R. H.
LABORATORY INVESTIGATION, 2010, 90 : 363A - 363A
[3] Case Report: SMARCA4 (BRG1)-deficient undifferentiated carcinoma of gallbladder with genetic analysis
Meng, Xiangpeng
Ma, Jia
Meng, Nan
Yun, Tianyu
Niu, Beifang
FRONTIERS IN ONCOLOGY, 2023, 13
[4] SMARCA4/BRG1 Deficient Thoracic Neoplasms: Spectrum Encompassing Carcinomas to Undifferentiated Tumors
Tandon, A.
Nambirajan, A.
Chandrashekhara, S.
Mohan, A.
Kumar, S.
Malik, P. S.
Jain, D.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S494 - S495
[5] Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers
Hulse, Michael
Elkins, Margot
Burtell, Jessica
Vykuntam, Komali
Vaddi, Kris
Combs, Andrew
Ito, Koichi
Scherle, Peggy
CANCER RESEARCH, 2023, 83 (07)
[6] SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study
Sun, Hongxia
Huo, Lei
Sweeney, Keith
Resetkova, Erika
Chai, Danial
Chen, Hui
Albarracin, Constance
Wu, Yun
Ding, Qingqing
LABORATORY INVESTIGATION, 2024, 104 (03) : S274 - S275
[7] SMARCA4(BRG1) and SMARCB1(INI1) Immunoexpression in TTF1 Negative Neuroendocrine Carcinoma
Alnoor, Fnu
Gandhi, Jatin
Solares, Jorge
Gradowski, Joel
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 816 - 817
[8] SMARCA4(BRG1) and SMARCB1(INI1) Immunoexpression in TTF1 Negative Neuroendocrine Carcinoma
Alnoor, Fnu
Gandhi, Jatin
Solares, Jorge
Gradowski, Joel
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 816 - 817
[9] The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms
Zheng, Lan
Zhang, Lin
Wang, Xiaohong Iris
Katz, Guy
Tandon, Nidhi
Zhao, Bihong
Lucci, Joseph
Ding, Jianmin
Zhang, Songlin
HUMAN PATHOLOGY, 2022, 124 : 45 - 55
[10] Immunophenotypical Analysis of SMARCA4 (BRG1) Deficient Non-Small Cell Lung Carcinoma Diagnosed on Cytology Specimens
Ogunbona, Oluwaseun
Lubin, Daniel
Reid, Michelle
Van Nostrand, Keriann
Schneider, Frank
Shi, Qiuying
LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 257 - 258

← 1 2 3 4 5 →